Skip to main content
. 2018 Aug 23;7(11):e1500107. doi: 10.1080/2162402X.2018.1500107

Figure 5.

Figure 5.

GW9662 boosts anti-PD-L1/PD-1 antibody efficacy in vivo. (a-d) Tumor study with treatment of GW9662 and anti-PD-L1. E0771 mammary tumor growth curve (a), representative tumor image (b) and tumor weight (c) upon harvest. Survival curve is shown in (d). Treatments are as follow. Sham: vehicle + anti-IgG (n = 13), vehicle + anti-PD-L1 (n = 13), GW + anti-IgG (n = 13) and anti-PD-L1 + GW (n = 13). (e-f) Tumor study with treatment of GW9662 and anti-PD-1. E0771 mammary tumor growth (e) and survival (f). Sham: vehicle + anti-IgG (n = 4), vehicle + anti-PD-1 (n = 4), GW + anti-IgG (n = 5) and anti-PD-1 + GW (n = 4). Data are mean± SEM. P values for the tumor growth curve in (a) indicate the statistics for the last measurement time point. P values for the survival analysis in (d) test the null hypothesis that the indicated two survival curves are identical.